The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo ...
PharmiWeb2d
The United Laboratories and Novo Nordisk announce…
The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) ...
Yahoo Finance10d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said ...
Pharmabiz2d
The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251
The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251: Guangdong, China Wednesday, March 26, 2025, 10:00 Hrs [IST] The United Laboratories Intern ...
PharmExec2d
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...
Business Insider3d
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The addition of a candidate targeting glucagon ... 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...